Moderna Inc
NASDAQ:MRNA
Intrinsic Value
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). [ Read More ]
The intrinsic value of one
MRNA
stock under the Base Case scenario is
39.47
USD.
Compared to the current market price of 103.29 USD,
Moderna Inc
is
Overvalued by 62%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Moderna Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Moderna Inc
| Current Assets | 10.6B |
| Cash & Short-Term Investments | 8.5B |
| Receivables | 688m |
| Other Current Assets | 1.5B |
| Non-Current Assets | 11.3B |
| Long-Term Investments | 6.1B |
| PP&E | 2.4B |
| Other Non-Current Assets | 2.8B |
| Current Liabilities | 3.1B |
| Accounts Payable | 310m |
| Accrued Liabilities | 1.5B |
| Other Current Liabilities | 1.3B |
| Non-Current Liabilities | 1.8B |
| Long-Term Debt | 843m |
| Other Non-Current Liabilities | 969m |
MRNA Profitability Score
Profitability Due Diligence
Moderna Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Moderna Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
MRNA Solvency Score
Solvency Due Diligence
Moderna Inc's solvency score is 98/100. The higher the solvency score, the more solvent the company is.
Score
Moderna Inc's solvency score is 98/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRNA Price Targets Summary
Moderna Inc
According to Wall Street analysts, the average 1-year price target for
MRNA
is 185.1 USD
with a low forecast of 68.68 USD and a high forecast of 451.5 USD.
Ownership
MRNA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MRNA Price
Moderna Inc
| Average Annual Return | 149.81% |
| Standard Deviation of Annual Returns | 227.11% |
| Max Drawdown | -80% |
| Market Capitalization | 39.4B USD |
| Shares Outstanding | 381 209 000 |
| Percentage of Shares Shorted | 6.31% |
MRNA News
Last Video News
Moderna Inc
Last Important Events
Moderna Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Moderna Inc
Company Profile
Moderna Inc
Country
Industry
Market Cap
Dividend Yield
Description
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.
Contact
IPO
Employees
Officers
The intrinsic value of one
MRNA
stock under the Base Case scenario is
39.47
USD.
Compared to the current market price of 103.29 USD,
Moderna Inc
is
Overvalued by 62%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
